Market Research Logo

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2019

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H1 2019

Summary

According to the recently published report 'Smoothened Homolog - Pipeline Review, H1 2019'; Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

Smoothened Homolog (Protein Gx or SMO) - Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.

The report 'Smoothened Homolog - Pipeline Review, H1 2019' outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 3, 2, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Immunology and Undisclosed which include indications Adenocarcinoma Of The Gastroesophageal Junction, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), Medulloblastoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Basal Cell Carcinoma (Basal Cell Epithelioma), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Leukemias, Peritoneal Cancer, Prostate Cancer, Small-Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Breast Cancer, Cirrhosis, Colon Cancer, Colorectal Cancer, Esophageal Cancer, Graft Versus Host Disease (GVHD), Lung Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Neuroendocrine Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Unspecified.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)
  • The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Smoothened Homolog (Protein Gx or SMO) - Overview
Smoothened Homolog (Protein Gx or SMO) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development
AlfaSigma SpA
F. Hoffmann-La Roche Ltd
Genentech Inc
Guangdong Zhongsheng Pharmaceutical Co Ltd
IMPACT Therapeutics Inc
Mayne Pharma Group Ltd
PellePharm Inc
Pfizer Inc
Sun Pharma Advanced Research Company Ltd
Smoothened Homolog (Protein Gx or SMO) - Drug Profiles
glasdegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSA-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GT-1708 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMP-5471 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
itraconazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
patidegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize SMO for Colon Cancer and Medulloblastoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Target SMO and HDAC for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize SMO for Colorectal Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Smoothened Homolog for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sonidegib phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
taladegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vismodegib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZSP-1602 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Smoothened Homolog (Protein Gx or SMO) - Dormant Products
Smoothened Homolog (Protein Gx or SMO) - Discontinued Products
Smoothened Homolog (Protein Gx or SMO) - Product Development Milestones
Featured News & Press Releases
Apr 01, 2019: PellePharm initiates pivotal phase 3 clinical trial of Patidegib topical gel in patients with gorlin syndrome
Jan 30, 2019: Tolsura (suba-itraconazole) antifungal capsule now available in the United States
Dec 18, 2018: Mayne Pharma announces US commercial rights for Suba-itraconazole in BCCNS
Dec 12, 2018: Mayne pharma receives FDA approval of Tolsura (Suba-Itraconazole capsules) for the treatment of certain fungal infections
Nov 23, 2018: FDA approves Pfizer’s Daurismo to treat acute myeloid leukaemia
Oct 15, 2018: Pellepharm presents updated data from two phase 2 studies demonstrating the potential of Patidegib topical gel to treat basal cell carcinomas in patients with gorlin syndrome and in patients with non-gorlin sporadic bccs
Oct 11, 2018: HedgePath Pharmaceuticals to present at the 2018 BioFlorida Annual Conference
Oct 09, 2018: HedgePath Pharmaceuticals pathway for filing SUBA BCCNS NDA clarified in Meeting with FDA
Aug 06, 2018: HedgePath Pharmaceuticals Announces Positive FDA Feedback from FDA Type-C Meeting and Files Pre-NDA Meeting Request
Jun 27, 2018: U.S. FDA Grants Priority Review for Pfizer’s New Drug Application for Glasdegib in Patients with Previously Untreated Acute Myeloid Leukemia
Jun 05, 2018: HedgePath Pharmaceuticals Granted Meeting with FDA to Discuss SUBA BCCNS Trial Data and Regulatory Pathway
May 21, 2018: HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage
May 16, 2018: PellePharm to present topical Patidegib and skin cancer epidemiological data at the 7th International Investigative Dermatology Meeting
May 14, 2018: HedgePath Pharmaceuticals Announces Expanded Patent Coverage
May 02, 2018: Mayne Pharma Announces FDA Acceptance of New Drug Application for Its Antifungal Suba-Itraconazole Capsule
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Indications, H1 2019
Number of Products under Development by Indications, H1 2019 (Contd..1), H1 2019
Number of Products under Development by Companies, H1 2019
Products under Development by Companies, H1 2019
Number of Products under Investigation by Universities/Institutes, H1 2019
Products under Investigation by Universities/Institutes, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Pipeline by AlfaSigma SpA, H1 2019
Pipeline by F. Hoffmann-La Roche Ltd, H1 2019
Pipeline by Genentech Inc, H1 2019
Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2019
Pipeline by IMPACT Therapeutics Inc, H1 2019
Pipeline by Mayne Pharma Group Ltd, H1 2019
Pipeline by PellePharm Inc, H1 2019
Pipeline by Pfizer Inc, H1 2019
Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2019
Dormant Products, H1 2019
Discontinued Products, H1 2019
List of Figures
Number of Products under Development by Stage of Development, H1 2019
Number of Products under Development by Therapy Areas, H1 2019
Number of Products under Development by Top 10 Indications, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Routes of Administration, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook